Company / Working Capital
Vir Biotechnology, Inc. Working Capital History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Working Capital
$421.3M
FY2025
5-year range
$421.3M / $2.0B
FY2021-FY2025
Trend
-54.3%
vs FY2024
Sector context
#104 of 213
Health Care
What the data says
At $421M, Vir Biotechnology, Inc.'s working capital ranks #104 of 213 in the Health Care sector. Working Capital has declined for 3 consecutive years, from $2.0B in FY2022 to $421M in FY2025.
Based on SEC 10-K filings.
$421M in FY2025 with a 5-year CAGR of -9.0%.
Declined from $1.4B to $421M over the past 2 years.
Health Care sector context is included.
Working Capital over time
Growth rates
- 3-Year CAGR
- -40.6%
- 5-Year CAGR
- -9.0%
- 10-Year CAGR
- -
Sector benchmark
#104 of 213 in Health CareTop 49% of 213This company $421.3M Sector average $934.6M
▼
-54.9% below sector average
Key checks
Key Insights
- Vir Biotechnology, Inc.'s working capital has declined for 3 consecutive years.
- 5-year CAGR of -9.0%, indicating a declining trend.
- In FY2025, working capital decreased 54.3% year-over-year.
- Ranks #104 out of 213 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -0.77 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Working CapitalValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $421.3M | -54.3% |
| FY2024 | $922.8M | -34.7% |
| FY2023 | $1.4B | -29.6% |
| FY2022 | $2.0B | +64.4% |
| FY2021 | $1.2B | +81.4% |
| FY2020 | $673.3M | +95.8% |
| FY2019 | $343.8M | +341.5% |
| FY2018 | $77.9M | - |
| FY2017 | - | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026